Anti-telomerase cancer therapy: MiRNA-1246 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of its target gene, 8/November/2016, 10.47 pm

Natural product therapy for Bone disorders: Parkia-javanica extract inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 8/November/2016, 10.43 pm
November 8, 2016
Carbon Monoxide therapy for Myocardial Infarction: Carbon Monoxide (CO) improves myocardial function after myocardial infarction via up-regulation of PNUTS, 9/November/2016, 7.14 am
November 9, 2016
Show all

Introduction: What they say: 

The 1989 Nobel prize winner in Chemistry, Prof. Thomas R. Cech from the BioFrontiers Institute, USA has published a research paper in the 13 December 2012 Nature (492(7428):285-9; and I.F: >42) stating that “The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity.”  This study provides mechanistic insights into how TPP1 regulates telomerase function.


What we say: 

In connection with this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: Anti-telomerase cancer therapy: MiRNA-1246 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of its target gene


Significance:

Given that: (1) over 90% human tumors overexpress immortality gene telomerase; (2) cancer causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a way to inhibit telomerase activity in human tumors, to increase the efficacy of anticancer therapy;  (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; (iv) a way to effectively treat cancers that are resistant to anti-cancer drugs; and (v) a way to effectively treat and eradicate metastatic progression of cancer.


Research Findings:

MiRNA-1246, by decreasing the expression of its target gene, it may suppress the expression of Tripeptidyl Peptidase 1 (TPP1). Thus, pharmacological formulations encompassing MiRNA-1246 activators may be used to treat human cancers that specifically overexpress immortality gene telomerase. 


Idea Proposed/Formulated (with factual evidence) byDr L Boominathan Ph.D.

CitationBoominathan, L., Anti-telomerase cancer therapy: MiRNA-1246 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of its target gene, 8/November/2016, 10.47 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com


Amount: $100#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How MiRNA-1246 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1)

100-guaranteed-to-work-if-not-cash-back

# Research cooperation

Comments are closed.